NEBCINE ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis1

299. Cystic fibrosis


Clinical trials : 1,695 Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-003882-10-FR
(EUCTR)
29/07/2015Evaluation of the efficacy of antibiotic treatments associated with the Nebcine® as intravenous injection only and / or monitoring of aerosols of Tobi® in order to optimize the therapeutic management of exacerbations in patients with cystic fibrosis .Evaluation of the effectiveness of a treatment involving one (or several ) antibiotic (s) with 14-day tobramycin ( Nebcine® ) by intravenous injection versus the same antibiotic treatment (s ) associated with only 5 days of tobramycin ( Nebcine® ) by intravenous injection followed tobramycin aerosol ( Tobi® ) for 9 days in the context of cystic fibrosis mucoviscidosis or cystic fibrosis
MedDRA version: 18.0;Level: LLT;Classification code 10068288;Term: Cystic fibrosis pulmonary exacerbation;System Organ Class: 100000004862;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Trade Name: NEBCINE
Product Name: NEBCINE
Other descriptive name: TOBRAMYCIN
Trade Name: NEBCINE
Product Name: NEBCINE
Other descriptive name: TOBRAMYCIN
Trade Name: NEBCINE
Product Name: NEBCINE
Other descriptive name: TOBRAMYCIN
Trade Name: NEBCINE
Product Name: NEBCINE
Other descriptive name: TOBRAMYCIN
Trade Name: TOBI
Product Name: TOBI
Other descriptive name: TOBRAMYCIN
CHRU de LilleNULLNAFemale: yes
Male: yes
Phase 2France